Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menjugate infant priming and booster schedule study
2005-000924-18Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease (3 arms), sponsored by Novartis. Primary endpoints: Memory antibody responder rate after booster: group 2 versus group 1 and Memory antibody responder rate after booster: group 3 versus group 1. Started Apr 2005; status: completed.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2005-000924-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000924-18.